112 related articles for article (PubMed ID: 27121790)
1. Glycerol Phenylbutyrate in Patients With Cirrhosis and Episodic Hepatic Encephalopathy: A Pilot Study of Safety and Effect on Venous Ammonia Concentration.
Ghabril M; Zupanets IA; Vierling J; Mantry P; Rockey D; Wolf D; O'Shea R; Dickinson K; Gillaspy H; Norris C; Coakley DF; Mokhtarani M; Scharschmidt BF
Clin Pharmacol Drug Dev; 2013 Jul; 2(3):278-84. PubMed ID: 27121790
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control.
Lee B; Rhead W; Diaz GA; Scharschmidt BF; Mian A; Shchelochkov O; Marier JF; Beliveau M; Mauney J; Dickinson K; Martinez A; Gargosky S; Mokhtarani M; Berry SA
Mol Genet Metab; 2010 Jul; 100(3):221-8. PubMed ID: 20382058
[TBL] [Abstract][Full Text] [Related]
3. Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy.
Rockey DC; Vierling JM; Mantry P; Ghabril M; Brown RS; Alexeeva O; Zupanets IA; Grinevich V; Baranovsky A; Dudar L; Fadieienko G; Kharchenko N; Klaryts'ka I; Morozov V; Grewal P; McCashland T; Reddy KG; Reddy KR; Syplyviy V; Bass NM; Dickinson K; Norris C; Coakley D; Mokhtarani M; Scharschmidt BF;
Hepatology; 2014 Mar; 59(3):1073-83. PubMed ID: 23847109
[TBL] [Abstract][Full Text] [Related]
4. Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Mokhtarani M; Diaz GA; Rhead W; Berry SA; Lichter-Konecki U; Feigenbaum A; Schulze A; Longo N; Bartley J; Berquist W; Gallagher R; Smith W; McCandless SE; Harding C; Rockey DC; Vierling JM; Mantry P; Ghabril M; Brown RS; Dickinson K; Moors T; Norris C; Coakley D; Milikien DA; Nagamani SC; Lemons C; Lee B; Scharschmidt BF
Mol Genet Metab; 2013 Dec; 110(4):446-53. PubMed ID: 24144944
[TBL] [Abstract][Full Text] [Related]
5. Glycerol phenylbutyrate efficacy and safety from an open label study in pediatric patients under 2 months of age with urea cycle disorders.
Longo N; Diaz GA; Lichter-Konecki U; Schulze A; Inbar-Feigenberg M; Conway RL; Bannick AA; McCandless SE; Zori R; Hainline B; Ah Mew N; Canavan C; Vescio T; Kok T; Porter MH; Berry SA
Mol Genet Metab; 2021 Jan; 132(1):19-26. PubMed ID: 33388234
[TBL] [Abstract][Full Text] [Related]
6. Ammonia control in children ages 2 months through 5 years with urea cycle disorders: comparison of sodium phenylbutyrate and glycerol phenylbutyrate.
Smith W; Diaz GA; Lichter-Konecki U; Berry SA; Harding CO; McCandless SE; LeMons C; Mauney J; Dickinson K; Coakley DF; Moors T; Mokhtarani M; Scharschmidt BF; Lee B
J Pediatr; 2013 Jun; 162(6):1228-34, 1234.e1. PubMed ID: 23324524
[TBL] [Abstract][Full Text] [Related]
7. Ammonia control in children with urea cycle disorders (UCDs); phase 2 comparison of sodium phenylbutyrate and glycerol phenylbutyrate.
Lichter-Konecki U; Diaz GA; Merritt JL; Feigenbaum A; Jomphe C; Marier JF; Beliveau M; Mauney J; Dickinson K; Martinez A; Mokhtarani M; Scharschmidt B; Rhead W
Mol Genet Metab; 2011 Aug; 103(4):323-9. PubMed ID: 21612962
[TBL] [Abstract][Full Text] [Related]
8. Fasting Blood Ammonia Predicts Risk and Frequency of Hepatic Encephalopathy Episodes in Patients With Cirrhosis.
Vierling JM; Mokhtarani M; Brown RS; Mantry P; Rockey DC; Ghabril M; Rowell R; Jurek M; Coakley DF; Scharschmidt BF
Clin Gastroenterol Hepatol; 2016 Jun; 14(6):903-906.e1. PubMed ID: 26707685
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults with cirrhosis.
McGuire BM; Zupanets IA; Lowe ME; Xiao X; Syplyviy VA; Monteleone J; Gargosky S; Dickinson K; Martinez A; Mokhtarani M; Scharschmidt BF
Hepatology; 2010 Jun; 51(6):2077-85. PubMed ID: 20512995
[TBL] [Abstract][Full Text] [Related]
10. Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disorders.
Mokhtarani M; Diaz GA; Rhead W; Lichter-Konecki U; Bartley J; Feigenbaum A; Longo N; Berquist W; Berry SA; Gallagher R; Bartholomew D; Harding CO; Korson MS; McCandless SE; Smith W; Vockley J; Bart S; Kronn D; Zori R; Cederbaum S; Dorrani N; Merritt JL; Sreenath-Nagamani S; Summar M; Lemons C; Dickinson K; Coakley DF; Moors TL; Lee B; Scharschmidt BF
Mol Genet Metab; 2012 Nov; 107(3):308-14. PubMed ID: 22958974
[TBL] [Abstract][Full Text] [Related]
11. Exposures of Phenylacetic Acid and Phenylacetylglutamine Across Different Subpopulations and Correlation with Adverse Events.
Wang X; Tseng J; Mak C; Poola N; Vilchez RA
Clin Pharmacokinet; 2021 Dec; 60(12):1557-1567. PubMed ID: 34125423
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study.
Kircheis G; Nilius R; Held C; Berndt H; Buchner M; Görtelmeyer R; Hendricks R; Krüger B; Kuklinski B; Meister H; Otto HJ; Rink C; Rösch W; Stauch S
Hepatology; 1997 Jun; 25(6):1351-60. PubMed ID: 9185752
[TBL] [Abstract][Full Text] [Related]
13. Glycerol phenylbutyrate treatment in children with urea cycle disorders: pooled analysis of short and long-term ammonia control and outcomes.
Berry SA; Lichter-Konecki U; Diaz GA; McCandless SE; Rhead W; Smith W; Lemons C; Nagamani SC; Coakley DF; Mokhtarani M; Scharschmidt BF; Lee B
Mol Genet Metab; 2014 May; 112(1):17-24. PubMed ID: 24630270
[TBL] [Abstract][Full Text] [Related]
14. [The effects of Helicobacter pylori infection on hyperammonaemia and hepatic encephalopathy in cirrhotic patients].
Wang LJ; Cai JT; Chen T; Lü B; Si JM
Zhonghua Nei Ke Za Zhi; 2006 Aug; 45(8):654-7. PubMed ID: 17074151
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of glycerol phenylbutyrate for management of urea cycle disorders in patients aged 2months to 2years.
Berry SA; Longo N; Diaz GA; McCandless SE; Smith WE; Harding CO; Zori R; Ficicioglu C; Lichter-Konecki U; Robinson B; Vockley J
Mol Genet Metab; 2017 Nov; 122(3):46-53. PubMed ID: 28916119
[TBL] [Abstract][Full Text] [Related]
16. Treating hepatic encephalopathy in cirrhotic patients admitted to ICU with sodium phenylbutyrate: a preliminary study.
Weiss N; Tripon S; Lodey M; Guiller E; Junot H; Monneret D; Mayaux J; Brisson H; Mallet M; Rudler M; Imbert-Bismut F; Thabut D;
Fundam Clin Pharmacol; 2018 Apr; 32(2):209-215. PubMed ID: 29239015
[TBL] [Abstract][Full Text] [Related]
17. Safety of ornithine phenylacetate in cirrhotic decompensated patients: an open-label, dose-escalating, single-cohort study.
Ventura-Cots M; Arranz JA; Simón-Talero M; Torrens M; Blanco A; Riudor E; Fuentes I; Suñé P; Soriano G; Córdoba J
J Clin Gastroenterol; 2013; 47(10):881-7. PubMed ID: 23751856
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of glycerol phenylbutyrate in pediatric patients 2 months to 2 years of age with urea cycle disorders.
Berry SA; Vockley J; Vinks AA; Dong M; Diaz GA; McCandless SE; Smith WE; Harding CO; Zori R; Ficicioglu C; Lichter-Konecki U; Perdok R; Robinson B; Holt RJ; Longo N
Mol Genet Metab; 2018 Nov; 125(3):251-257. PubMed ID: 30217721
[TBL] [Abstract][Full Text] [Related]
19. [Study of correlation between Helicobacter pylori infection and hyperammonemia and hepatic encephalopathy in cirrhotic patients].
Yang CS; Cao SY; He XJ; Wang YX; Zhang YL
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2007 Jul; 19(7):422-4. PubMed ID: 17631712
[TBL] [Abstract][Full Text] [Related]
20. L-ornithine and phenylacetate synergistically produce sustained reduction in ammonia and brain water in cirrhotic rats.
Davies NA; Wright G; Ytrebø LM; Stadlbauer V; Fuskevåg OM; Zwingmann C; Davies DC; Habtesion A; Hodges SJ; Jalan R
Hepatology; 2009 Jul; 50(1):155-64. PubMed ID: 19437490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
